Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Abstract
The recent approval of anti-programmed death-ligand 1 immunotherapy in combination with nab-paclitaxel for metastatic triple-negative breast cancer (TNBC) highlights the need to understand the role of chemotherapy in modulating the tumor immune microenvironment (TIME).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-3685
Entities
People
- Ana C Garrido-Castro
- Brent N. Rexer
- Ian E. Krop
- Ingrid A. Mayer
- Jing Zhou
- Jonathan D. Marotti
- Joshua Donaldson
- Justin M. Balko
- Kevin Shee
- Margaret L Axelrod
- Mark A. Pilkinton
- Melinda E. Sanders
- Mellissa J. Nixon
- Paula González Ericsson
- Riley E. Bergman
- Roberto Salgado
- Sara M Tolaney
- Sean Mackay
- Sherene Loi
- Simon A. Mallal
- Susan R. Opalenik
- Todd W. Miller
- Valerie M. Jansen
- Vandana G Abramson
- Violeta Sanchez
- Wyatt McDonnell
Organizations
- Dartmouth College
- Dartmouth–Hitchcock Medical Center
- Geisel School of Medicine
- Harvard Medical School
- National Institutes of Health
- Susan G. Komen for the Cure
- United States Department of Defense
- University of Melbourne
- Vanderbilt University
- Vanderbilt University Medical Center
- Vanderbilt-Ingram Cancer Center